liver-specific thrombopoietin targeting GalNAc-conjugated siRNA (Alnylam Pharmaceuticals/Johns Hopkins University School of Medicine)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameliver-specific thrombopoietin targeting GalNAc-conjugated siRNA (Alnylam Pharmaceuticals/Johns Hopkins University School of Medicine)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionThrombopoietin receptor inhibitors
TargetsThrombopoietin receptor
Therapy Area/IndicationsMyeloproliferative Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohns Hopkins University School Of MedicineAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMyeloproliferative Disorders

Other Information

ATC CodeN/A
Related LinksN/A